Legal & General Group Plc Acquires New Holdings in Dyne Therapeutics, Inc. $DYN

Legal & General Group Plc bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the second quarter, Holdings Channel.com reports. The institutional investor bought 97,940 shares of the company’s stock, valued at approximately $2,175,000.

Several other large investors also recently added to or reduced their stakes in DYN. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth $26,000. Strs Ohio bought a new stake in Dyne Therapeutics in the fourth quarter worth $51,000. Allworth Financial LP acquired a new position in Dyne Therapeutics during the second quarter worth $62,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Jason Rhodes sold 2,160,516 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 4,139,196 shares of company stock valued at $99,449,852. Corporate insiders own 9.46% of the company’s stock.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $24.28 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $11.92 and a twelve month high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The stock has a market capitalization of $4.53 billion, a PE ratio of -7.29 and a beta of 1.08. The stock has a 50-day simple moving average of $24.80 and a 200 day simple moving average of $20.36.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Analyst Ratings Changes

DYN has been the subject of a number of analyst reports. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley reduced their target price on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.